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Abstract
Background: The preterm microbiome is crucial to gut health and may contribute to necrotising enterocolitis
(NEC), which represents the most significant pathology affecting preterm infants. From a cohort of 318 infants,
<32 weeks gestation, we selected 7 infants who developed NEC (defined rigorously) and 28 matched controls.
We performed detailed temporal bacterial (n = 641) and metabolomic (n = 75) profiling of the gut microbiome
throughout the disease.
Results: A core community of Klebsiella, Escherichia, Staphyloccocus, and Enterococcus was present in all samples.
Gut microbiota profiles grouped into six distinct clusters, termed preterm gut community types (PGCTs). Each PGCT
reflected dominance by the core operational taxonomic units (OTUs), except of PGCT 6, which had high diversity
and was dominant in bifidobacteria. While PGCTs 1–5 were present in infants prior to NEC diagnosis, PGCT 6 was
comprised exclusively of healthy samples. NEC infants had significantly more PGCT transitions prior to diagnosis.
Metabolomic profiling identified significant pathways associated with NEC onset, with metabolites involved
in linoleate metabolism significantly associated with NEC diagnosis. Notably, metabolites associated with NEC
were the lowest in PGCT 6.
Conclusions: This is the first study to integrate sequence and metabolomic stool analysis in preterm neonates,
demonstrating that NEC does not have a uniform microbial signature. However, a diverse gut microbiome with a high
abundance of bifidobacteria may protect preterm infants from disease. These results may inform biomarker
development and improve understanding of gut-mediated mechanisms of NEC.
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Background
Survival after preterm birth is increasing, but this is as-
sociated with increased numbers of infants developing
necrotising enterocolitis (NEC) and late onset sepsis
(LOS), with ~10% and ~20% of very low birth weight
(VLBW) infants being affected, respectively [1]. NEC
and LOS are now responsible for more deaths after the
first week of life in extremely preterm infants than any
other single pathology [2], and both may result in signifi-
cantly impaired outcomes in survivors. Antecedent risk
factors for NEC vary, and the pathophysiology remains
poorly defined. Currently accepted staging, e.g. Bell’s
criteria, is deemed outdated [3] and there is increas-
ing acceptance that a clinical diagnosis of “NEC” may
simply be the final common pathway of multiple dis-
ease processes and LOS from gut bacterial transloca-
tion sharing similar processes [4].
Bacterial colonisation is necessary for the development
of NEC, and specific bacterial taxa have been associated
with onset, particularly those from the Proteobacteria
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phylum [5, 6] such as Enterobacter [7], Escherichia [8],
Sphingomonas [9], and Klebsiella sp [10]. Studies from
different research groups (and hence different neonatal
intensive care units) identify a variety of signatures po-
tentially associated with disease states. The two largest
studies exploring NEC have shown conflicting findings,
with no differences between NEC and control infants
(n = 163 patients (21 with NEC), 482 samples) in a de-
naturing gradient gel electrophoresis (DGGE) and cul-
ture exploration [11] and more recently an increased
relative abundance of Gammaproteobacteria and re-
duced Negativicutes (n = 166 patients, 3587 stools) [6].
Moving beyond 16S rRNA bacterial profiling, a metage-
nomic (shotgun sequencing) study of NEC samples dur-
ing an apparent outbreak found no distinct microbial
strain in NEC infants at the time of diagnosis [12].
Studies have also reported an absence of “pathogenic”
bacteria in tissue resections from NEC infants [13] and
no difference in the total bacterial load [14].
Previous studies utilising metabolomics to understand
NEC pathogenesis and identify potential biomarkers are
limited, with no published data on stool metabolomics.
However, Morrow et al. (2003) coupled bacterial profiling
of stool to metabolomic analysis of matched urine, show-
ing early dysbiosis of the bacterial community and a high
alanine to histidine ratio that was associated with micro-
bial characteristics and good overall prediction of NEC
[5]. Other metabolomic studies have utilised serum/
plasma, employing either LCMS or gas chromatograph
MS (GCMS), showing metabolomic profiles differ in dis-
ease compared to controls, but robust biomarkers were
not found [15, 16].
To further progress understanding of the bacterial and
host processes involved in NEC, we recruited a large co-
hort of preterm infants sampling stool daily where pos-
sible (n = >300 patients/>3000 samples) capturing key
health related issues with precise definitions. Using strict
classification for NEC and only including patients with
robust temporal sampling before and after disease
diagnosis, we present comprehensive longitudinal gut
microbiome data on 641 samples from those with dis-
ease (n = 7) and well-matched non-diseased controls
(n = 28). A subset of 75 samples (n = 16) also underwent
ultra performance liquid chromatography mass spectrom-
etry (UPLC-MS). We hypothesised that there would be
detectable and coherent differences in bacterial and meta-
bolomic profiles between healthy and diseased infants be-
fore the diagnosis of NEC, with associated bacterial
signatures potentially predictive of health or disease onset.
Results
Bacterial Profiling
Enterobacteriaceae, Escherichia, Enterococcus, and
Staphylococcus were present in every sample (core
microbiome). The unclassified Enterobacteriaceae was
cultured and identified by Matrix-assisted laser de-
sorption/ionisation time-of-flight mass spectrometry
(MALDI-TOF-MS) and full-length 16S sequencing as
Klebsiella (K. oxytoca and K. pneumoniae). The devel-
oping gut microbiome in patients diagnosed with NEC
was highly dynamic and individual, with no clear causative
organism identified in the patients diagnosed with NEC
(Additional file 1: Figure S1 and Additional file 2:
Table S1). Comparably, the bacterial profiles from
each control patient showed a high degree of intra-
and inter-patient variability, with large temporal shifts
in the core and satellite operational taxonomic units
(OTUs) (Additional file 3: Figure S2).
To further explore the complexity in the developing
preterm microbiome, we employed novel clustering ana-
lysis to ascertain preterm gut community types (PGCTs).
Such approaches have been successfully applied to re-
duce the dimensionality of complex datasets, allowing
robust analysis of temporal microbiome development
and in determining the primary drivers of community
structure (e.g. demographics, day of life, or disease)
[17, 18]. We found all samples grouped into six discrete
clusters (Fig. 1a; gap statistic Additional file 4: Figure S3).
Each cluster, defined as a PGCT, was grouped by as fol-
lows: dominance of Klebsiella (PGCT 1), dominance of
both Klebsiella and Enterococcus (PGCT 2), dominance of
Staphylococcus (PGCT 3), dominance of Enterococcus
(PGCT 4), dominance of Escherichia (PGCT 5), and
mixed population with high relative abundance of Bifido-
bacterium (PGCT 6) (Fig. 1a; individual PGCT heatmaps
Additional file 5: Figure S4). The number of observed
OTUs was comparable between all PGCTs with the ex-
ception of PGCT 6, which had a significantly higher rich-
ness and diversity (P = >0.001) (Fig. 1b). Notably, this
pattern in the Shannon diversity was uniform with in-
creasing age (Additional file 6: Figure S5). Further analysis
of the specific OTUs associated with each PGCT were in
accordance with the heatmap analysis, with PGCTs 1, 3, 4
and 5 all characterised by significantly (P = <0.001) higher
relative abundances of a single core OTU (Fig. 1c). PGCT
2 is further characterised by significantly (P = <0.001)
greater relatively abundances of two core OTUs (Klebsiella
and Enterococcus). PGCT 6 is uniquely characterised by
the significantly (P = <0.001) high relative abundance of a
Bifidobacterium OTU, as well as significantly (P = <0.001)
higher relative abundances of Clostridium spp., Streptococ-
cus spp., and Lactobacillus spp. (Fig. 1c).
Using network analysis with 10 days prior to disease
diagnosis to classify samples as “PreNEC” (based on our
previous work [19]), we were unable to confidently as-
sign any PGCT to the PreNEC samples compared to all
the control samples (Fig. 2a, b). PGCT 2 (fraction 0.16)
and PGCT 5 (fraction 0.09) were most associated with
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subsequent NEC diagnosis (Fig. 2a). While no specific
PGCT was associated with disease, PGCT 6 was not
found in any sample from NEC patients prior to diagnosis.
The only occurrence of PGCT 6 in a patient diagnosed
with NEC occurred in patient 199 22 days following diag-
nosis (Fig. 2b). PGCT 6, which represents a diverse com-
munity high in relative Bifidobacterium abundance,
occurred throughout the control population from early to
late samples. While no single PGCT was specifically asso-
ciated with NEC, the number of transitions between
PGCTs was significantly increased (P = 0.043) prior to
NEC diagnosis, compared to matched controls over the
same timeframe. The temporal development of Shannon
diversity increased in control infants, but reduced in the
NEC samples (Additional file 7: Figure S6).
Interestingly, the relative abundance of Staphylococcus
decreased in all groups following birth, with few samples
containing a high relative abundance following day 25 of
life. This was reflected in PGCT 3 (Staphylococcus domi-
nated), which was the only PGCT associated with age.
Additionally, no statistical difference in the relative
abundance of any OTU was found between vaginal and
caesarean section delivery from samples collected in the
initial week of life. Similarly for the alpha diversity, while
the Shannon diversity of vaginally delivered infants was
higher than those delivered by caesarean section, this in-
crease was not significant (Additional file 8: Figure S7).
No significant difference was also found in the alpha di-
versity of the gut microbiome between infants born at
different gestational ages (P = 0.16).
Fig. 1 Analysis of each of the six preterm gut community types (PGCT). a Heatmap showing the six PGCTs and the status. Status based on
disease or control; Control = pink, DControl = green, PreNEC = blue, and PreLOS = purple. Top 25 most abundant OTUs shown. b Boxplot analysis
of the observed OTUs and Shannon diversity showing each PGCT. P values based on the Kruskal-Wallis test show a significant increase in number
of OTUs and Shannon diversity in PGST 2. c Boxplot analysis of the eight most significantly distinct OTUs in each PGST. ***Represents a
Kruskal-Wallis P value ≤ 0.001
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Metabolite profiling
Mummichog analysis identified several pathways signifi-
cantly associated with NEC. Orthogonal partial least
squared-discriminatory analysis (OPLS-DA) analysis of
all features identified as significant by Mummichog from
samples at TP3 (disease diagnosis) showed clear cluster-
ing based on disease status (Fig. 3a). For NEC diagnosis
the five features with the largest VIP scores and, thus
most discriminatory power, corresponded to two metab-
olites from C21-steroid hormone biosynthesis and lino-
leate metabolism pathways, two metabolites from the
linoleate metabolism pathway, and one metabolite from
the leukotriene metabolism and prostaglandin formation
from arachidonate pathway. Further analysis of these five
features at all five time points showed significantly in-
creased levels at diagnosis compared to all the control
samples, with the total ion intensity increased through
each time point prior to disease and reduced following
diagnosis and treatment (Fig. 3b–f ). The five most sig-
nificant metabolites associated with NEC diagnosis were
compared with each PGCT using data from all time
points, showing clear concordance with the 16S bacterial
profiling data (Fig. 4). The features most associated with
NEC were reduced in relative abundance in PGCT 6.
Discussion
The extensive longitudinal sampling employed in this
study demonstrated the extent of intra- and inter-
individual variation in the development of the preterm
gut microbiota in both health and disease. To facilitate
comparisons between samples prior to disease diagnosis
and from healthy (control) infants, we clustered samples
into one of six specific PGCT based on the bacterial
profiles. The PGCT analysis showed the majority of pa-
tients exhibited multiple PGCTs during the study, with
only one patient (control 234) having the same PGCT
(PGCT 1) throughout the entirety of sampling. Indeed,
controls generally showed significantly increased stability
compared to NEC infants prior to disease diagnosis.
No specific microbial signature was found prior to the
diagnosis of NEC, compared to matched healthy con-
trols. Although no microorganism has been reproducibly
Fig. 2 Dynamics of the microbiome through each preterm gut community type (PGCT) in patients diagnosed with NEC compared to matched
controls over the initial weeks of life. a Transition network analysis showing PGCTs in the PreNEC samples. Approximated as a Markov chain with
subject-independent transition probabilities. Arrow weights reflect the transition probabilities from the existing PGCT to the subsequent PGCT in
next sample. Size of circle reflects the relative number of samples associated with that PGCT. Increasing fractions represent PGCT that have rela-
tively larger number of predisease diagnosis samples. b Visualisation of the PGCTs in each individual patient overtime. Red dotted lines represent
day of NEC diagnosis. Only samples up to day 50 of life are included. Patient 180 died during the study
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associated with NEC, many studies have reported poten-
tial associations with specific taxa [7, 9, 10, 20, 21], in-
cluding a recent large multicentre study which found
increased Gammaproteobacteria and Negativicutes prior
to NEC [6]. The latter study conducted analysis at the
class level, whereas the current study used genus level
taxonomic classification. Notably, analysing the current
dataset at class level showed no significant difference in
the relative abundance of Gammaproteobacteria (class)
between the preNEC and control samples (Additional
file 9: Figure S8). It should also be noted that by nature
of “association” between specific taxa and NEC, the re-
ported taxa are not ubiquitously increased in NEC and
will also be present in comparable abundance in some
healthy controls, which is in accordance with our data.
Thus, the presence of such taxa alone may not improve
our understanding of NEC pathogenesis. Our study is
also consistent with another large preterm cohort (163
infants, 21 with NEC, analysing 482 samples) who report
no associations using molecular DGGE profiling [11]
and a recent powerful metagenomic study with analysis
to the strain level [12, 22]. The latter metagenomic study
Fig. 3 LCMS metabolomic features associated with NEC diagnosis. a OPLS-DA of NEC and matched control samples at time point 3 (diagnosis).
b–f Box plot analysis showing the temporal development of the five most significant features associated with NEC diagnosis. Lettering represents
Tukey’s pairwise comparison results, where groups that do not share a letter are significantly different. NEC diagnosis is significantly different from
control samples. All time points included
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Fig. 4 (See legend on next page.)
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highlights the importance of lower taxonomic level ana-
lysis in disease association studies. Further characterisa-
tion of Escherichia coli isolates from NEC and control
infants in this study support the finding that each infant
harboured unique strains (Additional file 10: Figure S9).
While no specific microbial signature or taxa was evi-
dent in disease, the instability of the developing gut
microbiome in NEC infants may be a “trigger” initiating
and promoting a constant exaggerated inflammatory re-
sponse, ultimately leading to tissue damage. Such find-
ings need to be validated and quantified in independent
cohorts, using rigorous longitudinal sampling prior to
disease and similarly in controls.
Although no specific taxa was elucidated in bacterial
profiling, metabolomic profiling showed that the five
most discriminatory metabolites in the NEC samples at
the time of diagnosis were significantly elevated com-
pared to all the control samples. While the metabolites
were most significant at diagnosis, the metabolites in-
creased in intensity prior to diagnosis and reduced fol-
lowing NEC diagnosis. The temporal increase in
metabolites prior to diagnosis, whilst levels in the con-
trol samples remained consistently low, suggests such
metabolites may be predictive of disease onset. This
finding offers potential in biomarker development for
detecting the risk NEC, which precedes the clinical diag-
nosis. Based on the findings here, the progression to-
ward NEC may be detected between 1–2 weeks prior to
current clinical diagnosis, which is consistent with the
previous data [22]. Such findings require validation in
large multicentre studies, but the finding that 4/5 me-
tabolites most associated with NEC were involved in
linoleate metabolism is intriguing given that trans-10,
cis-12-conjugated linoleic acid (t10c12-CLA) nega-
tively impacts on lipid metabolism, mediated by alter-
ations in gut microbiome [23]. As more metabolomic
investigations are performed, the mechanism of lino-
leate metabolism in an inflammatory-mediated dam-
age may be better elucidated, but the results of this
study support the concept that it is, at least in part,
mediated by the microbiome.
Analysing a large number of samples from healthy
control infants revealed a novel healthy microbial signa-
ture (PGCT 6), characterised by dominance of bifidobac-
teria and a significantly higher overall diversity. In
accordance with existing data, we found that control in-
fants have increasing diversity whereas patients diag-
nosed with NEC have significantly reduced diversity
while on the NICU [10, 19, 20], although the micro-
biome of NEC infants converge to that of controls
within 1 year following NICU discharge [24]. As well as
bifidobacteria, PGCT 6 also had significantly higher rela-
tive abundance of lactobacilli. Interestingly, because of
the associated health benefits, these genera are the most
common bacteria used in manufactured probiotic prod-
ucts [25]. The metabolomic profiling showed high con-
cordance with the 16S bacterial profiling results.
Strikingly, the metabolites most associated with NEC
were significantly reduced in PGST 6 and the metabo-
lites most associated with control were increased in
PGST 6. This suggests that changes in the microbial
community have a direct impact on the metabolic func-
tioning on the host, which may ultimately contribute to
disease pathophysiology.
Despite the recent trial showing no effect of supple-
mental Bifidobacterium breve [26], probiotics containing
Bifidobacterium spp. have generally shown reduced inci-
dences of NEC [27, 28] and bifidobacteria are known to
play fundamental roles in the development and mainten-
ance of a healthy gut microbiome [29, 30]. Thus, the
high abundance of bifidobacteria may contribute to the
improved health status by aiding gut maturation and
preventing over-expression of potentially damaging
pathways, although it is also possible that a higher abun-
dance of bifidobacteria simply acts as a marker for a
more healthy gut, rather than being directly causative in
preterm infants. This is supported by the finding in this
study that prostaglandin formation is significantly in-
creased at NEC diagnosis and reduced in PGCT 6, with
this pathway known to mediate inflammation [31, 32].
Caesarean or vaginal delivery did not significantly alter
the preterm gut microbiome, even in the initial weeks of
life, although PGCT 6 did occur more frequently in vagi-
nally delivered infants compared to caesarean section
(42 vs. 25, respectively).
Despite the collection of >3000 samples from >300
infants, the number of infants diagnosed with a dis-
ease from this cohort remains small due to both ap-
plication of a strict definition of disease states and
the inclusion criteria requiring robust temporal sam-
pling prior to and following disease diagnosis. The ex-
tent of inter-individual microbial variability in both
healthy and diseased infants suggests that no specific
bacterial signature is likely to cause NEC in our unit,
and this finding is unlikely to be influenced by add-
itional cases of NEC.
(See figure on previous page.)
Fig. 4 Comparison of significant LCMS metabolites associated with NEC and the PGCT determined by 16S bacterial profiling of the respective
sample. Samples from all time points included in the analysis. a, b C21-steroid hormone biosyntehesis and linoleate metabolism pathways. c, d
Linoleate metabolism pathways. e Leukotriene metabolism and prostagladlin formation from arachidonate pathway. PGCT 6 represents the
community type associated with exclusively healthy samples
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Conclusions
No consistent microbial signature or taxa was associated
with NEC, but the number of PGCT transitions, and
thus microbiome instability, was significantly increased
in NEC and may contribute to, or be a marker of, the
inflammatory-mediated damage in NEC pathogenesis. A
novel diverse bacterial community with high relative
abundance of bifidobacteria was found only in healthy
samples. The metabolomics and 16S data was highly
concordant, where metabolites associated with NEC
were significantly reduced in the healthy PGCT. Strat-
egies aiming to improve outcomes in preterm infants
which focus on attempts to promote healthy PGCT pro-
files, rather than focusing on PGCTs potentially associ-
ated with later disease, are warranted.
Methods
Participants and study design
All infants were cared for in the neonatal intensive
care unit (NICU) of the Royal Victoria Infirmary.
Standardised feeding, antibiotic and antifungal guide-
lines were used as described previously [19]. All sam-
ples were collected before any probiotic was used on
the unit. Stool samples and clinical data were col-
lected from 318 preterm infants. NEC was categorized
by at least one senior clinician and two additional se-
nior research clinicians by conducting case reviews,
reviewing notes, X-ray and operative findings and
classified as either surgical or medical (no surgery).
Complete agreement and presence of unequivocal radio-
graphic signs (pneumatosis) was required for medical
cases. All demographic information is summarised in
Table 1, and full demographic information for each patient
is presented in Additional file 11: Table S2.
Seven well-sampled cases of NEC were selected and
each matched to four well-sampled controls based on
gestational age (GA; +/− 1 week), birth weight, and de-
livery mode. The 35 infants contributed a total 641 ana-
lysed stool samples. Samples were stored immediately at
−20 °C and long-term at −80 °C, with all samples having
comparable collection/storage. 16S rRNA gene bacterial
profiling was performed on all the samples in the study.
Metabolomic profiling was performed on a subset of 16
infants (75 stools), 6 NEC and 10 matched controls.
Samples were selected for analysis relative to disease
diagnosis at day of life (DOL) −14 (time point 1; TP1), −7
(TP2), 0 (TP3), +7 (TP4), and +14 (TP5), and matched by
DOL alone in controls.
16S rRNA gene Bacterial Profiling
Nucleic acid extraction of stool was carried out on
100 mg of sample using the PowerLyzer™ PowerSoil®
DNA Isolation Kit (MoBio, CA, USA) in accordance
with the manufacturer’s instructions. Bacterial profiling
utilised the 16S rRNA gene targeting variable region four
based on the Schloss wet-lab MiSeq SOP and resulting
raw fastq data were processed using Mothur (version
1.31.2) as described previously [33]. Briefly, combined
reads were trimmed to 275 reads with 0 ambiguous
bases. Chimeric sequences were detected by Chimera.u-
chime and removed from downstream analysis. Align-
ment was generated via the Silva v4 database [34] and
Chloroplast, Mitochondria, unknown, Archaea, and
Eukaryota linages were removed from the analysis. In
total, 44,515,418 reads were obtained and raw sequences
were deposited in MG-RAST under the accession num-
bers 4516545.3-4516585.3.
UPLC-MS metabolomic profiling
Metabolomic profiling was performed as previously de-
scribed [24]. Briefly, 100 mg stool was homogenised (80%
methanol), vortexed for 15 min, centrifuged (10,000 × g),
and lyophilised. Reverse-phase ultra-performance LCMS
tandem mass spectrometry (UPLC-MS/MS) was per-
formed using an Accucore C18 column (2.6 μm, 150 ×
2.1 mm) at 40 °C, 3.0 μl injection, and 300 μl/min flow
rate. Gradients increased from 5% acetronitrile (ACN) to
95% ACN over 22 min, followed by 8 min wash and re-
equilibration. Samples were run randomly in triplicate on
a Q-Exactive (Thermo) using HESI with high resolution
(70,000) positive and negative switching. The mass range
was set from 100–1000 m/z. SIEVE (Version 2.2 beta) was
used to process the Thermo RAW files by component ex-
traction detecting a total of 11,612 components (8343
positive and 3269 negative).
Bioinformatic and statistical analysis
Analysis and visualization of microbiome communities
was conducted in R [35], utilizing the phyloseq package
[36] to import sample data and calculate alpha- and
beta-diversity metrics. Each sample was rarefied to 4397
reads. Significance of categorical variables were deter-
mined using the non-parametric Mann-Whitney test for
two category comparisons or the Kruskal-Wallis test
Table 1 Summary of patient samples and demographic per
group
Control (n = 28) NEC (n = 7) P value
Number of stool samples 520 121 –
Gestation (weeks)a 27 (24–30) 26 (23–30) 0.599
Birth weight (g)a 910 (545–1810) 760 (500–1470) 0.416
Birth mode (CS/vaginal) 15/13 3/4 1.0
Gender (male/female) 20/8 3/4 0.345
Antibiotic prediagnosis
(days)a
– 14 (2–26) –
Antibiotic total (days)a 4.5 (2–31) 29 (6–44) 0.0002
aMedian (range)
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when comparing three or more categories. All p values
were adjusted for multiple comparisons with the FDR
algorithm.
An R script was implemented and made publicly avail-
able by DiGiulio et al. [17] was employed for linear
mixed-effects modelling, partition around medoid based
clustering, and Markov chain modelling to cluster all the
samples within the study into PGCTs and determine
temporal development in health and disease. Bray-Curtis
was used to calculate the distance between all the sam-
ples, and this was denoised by extraction of the most
significant principal coordinates analysis (PCoA) eigen-
vectors before applying the PAM algorithm. Gap statistic
was used to determine the number of clusters. Ten days
prior to diagnosis of disease, network analysis was used
to classify PreNEC, based on previous data [19]. To de-
termine if the stability was potentially contributing to
the disease pathophysiology, the total number of unique
PGCTs and the number of transitions between PGCTs
were compared for NEC patients, to matched controls.
Only the pre diagnosis samples and control samples in
the first 28 days of life were included (last predisease
sample was day of life 28).
UPLC-MS data was filtered to include only m/z fea-
tures that occurred in >20% of samples. Metabolite an-
notation and pathway enrichment was performed using
Mummichog [37]. Mummichog was used to determine
significant pathways at TP3 by comparing NEC vs. con-
trol. Only pathways identified in Mummichog were in-
cluded in subsequent analysis. SIMCA 13.0 (Umetrics,
Stockholm, Sweden) was used to model the metabolo-
mics dataset by first plotting an unsupervised principal
coordinate analysis (PCA) and if clear grouping was ap-
parent a orthogonal partial least squared-discriminatory
analysis (OPLS-DA) was performed. Only OPLS-DA
with R2 > 0.8 and Q2 > 0.5 were considered robust and
predictive, respectively. The variable importance plot
(VIP) was used to determine the five metabolites most
associated with each class [38]. MiniTab 17 was used to
generate box plots and determine the significance by
Tukey’s method for multiple comparisons.
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confirmatory purposes. (TIF 655 kb)
Additional file 11: Table S2. Full demographics per patient. (XLSX 49 kb)
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